⌘K
t
Aptamer Group plc announced the results of its 2025 Annual General Meeting, held on 27 November 2025 at 11:00 am. At this meeting, all resolutions put to shareholders were duly passed. The Notice of Meeting was sent to shareholders on 3 November 2025, and full poll results will be made available on the company's website later today.
| Date | 27 Nov 2025 |
| Time | 13:01:04 |
| Category | AGMs and other meetings |
| ID | 3251J |
27 November 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Results of 2025 Annual General Meeting
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 11:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.
Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker Andrew Thacker / Guy McDougall |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/